RespireRx Pharmaceuticals Inc.
OperatingBiotech · Glen Rock, NJ
Financials
FY2010–FY2022 · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 5 earlier years are in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Cap table
Share counts as of Sep 30, 2023| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Preferred Stockpreferred | 6,164 | — | 100.0% | — |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- Richard Purcell526K Apr 2022 → 518K (8927.3%) Apr 2023
- Arnold Lippa Family Trust of 200723M Apr 2022 → 58M (991749.3%) Apr 2023
- Jeff E. Margolis21M Apr 2022 → 56M (963744.8%) Apr 2023
- Jeff Margolis Trusts21M Apr 2022 → 56M (963744.8%) Apr 2023
- Marc Radin5.3M Apr 2022 → 30M (521725.1%) Apr 2023
Principal holders% as the filing states it, Apr 17, 2023
- Arnold Lippa Family Trust of 200757,511,542 Common Stock37.0%of
- Jeff E. Margolis55,887,559 Common Stock36.2%of
- Jeff Margolis Trusts55,887,559 Common Stock36.2%of
- Marc Radin30,254,840 Common Stock20.5%of
- Richard Purcell517,691 Common Stock0.36%of
- David Dickason200,000 Common Stock0.14%of
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
SEC filings
View all 121 filings on EDGAR- Form 10-QNov 17, 20230001493152-23-041875EDGAR
- Form 10-QAug 21, 20230001493152-23-029607EDGAR
- Form 10-QMay 22, 20230001493152-23-018545EDGAR
- Form 10-KApr 17, 20230001493152-23-012542EDGAR
- Form 10-QNov 17, 20220001493152-22-032757EDGAR
- Form 10-QAug 22, 20220001493152-22-023726EDGAR
- Form 10-QMay 23, 20220001493152-22-014786EDGAR
- Form 10-KApr 15, 20220001493152-22-010053EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.